English
|
Español
English
|
Español
Insurance
Marketing
Pharmaceuticals
Technology/Innovation
Regulatory
Community
Janssen
Press release submission
| Dec 29, 2021
Janssen Submits Biologics License Application to U.S. FDA Seeking Approval of Teclistamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Press release submission
| Dec 22, 2021
FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
Press release submission
| Aug 19, 2021
Janssen Presents Phase 1 Results for RYBREVANT™ (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer with MET Exon 14 Skipping Mutations
Press release submission
| May 21, 2021
RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission
| Jan 16, 2019
JANSSEN: Announces European Commission approval of ERLEADA®(apalutamide) for non-metastatic castration-resistant prostate cancer patients who are at high risk of developing metastatic disease
Press release submission
| Dec 6, 2018
JANSSEN: DARZALEX® (daratumumab) Combination Regimens Show Positive Results for Newly Diagnosed and Relapsed Patients with Multiple Myeloma
Trending
+
Community
Patient Daily
| Apr 17, 2025
ENT Practice Expert: OTO Forum 2025 will feature 'at least four topics that stand out as vital for doctors'
+
Pharmaceuticals
Patient Daily
| Apr 17, 2025
UCSF neurosurgeon: 'The idea that 340B is about helping the poor is a fiction'
+
Pharmaceuticals
Patient Daily
| Apr 22, 2025
National Consumers League CEO: 340B program abuse is 'a financial bonanza for non-profit hospitals'
+
Pharmaceuticals
Patient Daily
| Apr 23, 2025
State Sen. Baldacci: 340B reform ‘could help hospitals alone to the tune of 50 to 70 million per year'
